William D. Lubell

Dr. William D. Lubell

Full Professor, Depatment of Chemistry, Université de Montréal
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2002 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
PDPauline Dergham
Pauline Dergham
BEBenjamin Ellezam
Benjamin Ellezam
CECharles Essagian
Charles Essagian
HAHovsep Avedissian
Hovsep Avedissian
William D. LubellWilliam D. Lubell
William D. Lubell
LMLisa McKerracher
Lisa McKerracher
The Rho signaling pathway regulates the cytoskeleton and motility and plays an important role in neuronal growth inhibition. Here we demonstrate that inactivation of Rho or its downstream target Rho-associated kinase (ROK) stimulated neurite growth in primary cells of cortical neurons plated on myelin or chondroitin sulfate proteoglycan substrates. Furthermore, treatment either with C3 transferase (C3) to inactivate Rho or with Y27632 to inhibit ROK was sufficient to stimulate axon regeneration and recovery of hindlimb function after spinal cord injury (SCI) in adult mice. Injured mice were treated with a single injection of Rho or Rho-associated kinase inhibitors delivered in a protein adhesive at the lesion site. Treated animals showed long-distance regeneration of anterogradely labeled corticospinal axons and increased levels of GAP-43 mRNA in the motor cortex. Behaviorally, inactivation of Rho pathway induced rapid recovery of locomotion and progressive recuperation of forelimb–hindlimb coordination. These findings provide evidence that the Rho signaling pathway is a potential target for therapeutic interventions after spinal cord injury.

1 September 1997 in Tetrahedron
Verified
Journal Article
Closed access
SHStephen Hanessian
Stephen Hanessian
GMGrant McNaughton-Smith
Grant McNaughton-Smith
HLHenry-Georges Lombart
Henry-Georges Lombart
William D. LubellWilliam D. Lubell
William D. Lubell

1 January 1991 in Tetrahedron: Asymmetry
Verified
Journal Article
Closed access
William D. LubellWilliam D. Lubell
William D. Lubell
MKMasato Kitamura
Masato Kitamura
RNRyoji Noyori
Ryoji Noyori

1 July 2011 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
CPCaroline Proulx
Caroline Proulx
DSDavid Sabatino
David Sabatino
RHRobert Hopewell
Robert Hopewell
JSJochen Spiegel
Jochen Spiegel
YRYésica García Ramos
Yésica García Ramos
William D. LubellWilliam D. Lubell
William D. Lubell
Azapeptides are peptide analogs in which one or more of the amino residues is replaced by a semicarbazide. This substitution of a nitrogen for the α-carbon center results in conformational restrictions, which bend the peptide about the aza-amino acid residue away from a linear geometry. The resulting azapeptide turn conformations have been observed by x-ray crystallography and spectroscopy, as well as predicted based on computational models. In biologically active peptide analogs, the aza-substitution has led to enhanced activity and selectivity as well as improved properties, such as prolonged duration of action and metabolic stability. In light of these characteristics, azapeptides have found important uses as receptor ligands, enzyme inhibitors, drugs, pro-drugs, probes and imaging agents. Recent improvements in synthetic methods for their procurement have ushered in a new era of azapeptide chemistry. This review aims to provide a historical look at the development of azapeptide science along with a focus on recent developments and perspectives on the future of this useful tool for medicinal chemistry.

1 April 2003 in Tetrahedron
Verified
Journal Article
Closed access
RMRosa E. Meléndez
Rosa E. Meléndez
William D. LubellWilliam D. Lubell
William D. Lubell

1 January 1996 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EBEric Beausoleil
Eric Beausoleil
William D. LubellWilliam D. Lubell
William D. Lubell